Customize your experience
You decide what information you want to see on your Sanofi Campus
More about science
Choose a therapeutic area to find related scientific content
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Allergic Rhinitis
.svg 767w, /dam/jcr:614586a4-9d5b-4635-8e61-0cafde125c35/asthma%20(6).svg 1200w)
Asthma
Atopic Dermatitis
Cardiovascular
COPD
Chronic Spontaneous Urticaria
Diabetes
Eosinophilic Esophagitis
Microbiota & Probiotics
Multiple Sclerosis
.svg 767w, /dam/jcr:61a43d09-b3d3-48bb-ab3f-c46e493445f9/nasal%20(1).svg 1200w)
Nasal Polyps
Multiple Myeloma
Prurigo Nodularis
Rare Diseases
Transplant
Vaccines
Latest trends
Explore the most popular scientific articles and videos among Campus Sanofi users
2022 ACC Expert Consensus on ASCVD Management
A Meningitis Survivor: Daniel Advocates for Prevention
A narrative review for clinicians on insulin management for T2DM during Ramadan
A promising biomarker in MS: Neurofilament light chain
About Type 2 Inflammation - Atopic Dermatitis
Achievement of ESC/EAS LDL-C Treatment Goals After an ACS with Statin and Alirocumab
Achievement of lipid modification goals with Statins & Ezetimibe
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice
Acute Medical Illness: Advanced Age Alone Predicts Venous Thromboembolism Similar to Existing Risk Assessment Models
Adherence and persistence analysis in patients treated with DAPT
Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes (Solimix)
Events
Stay up to date and register for the latest events and view webinar recordings
GAED 2023
Diatour Programme
CardioRisk WebApp
Venous Thromboembolism Burden
Sanofi Thrombosis Summit
World Diabetes Day
Diatour Inquiry Form
Hypertension and CVD
Ultimate Need for Intensification
What is Epilepsy
Saudi Experience with Aubagio
Diabetes Guidelines in Ramadan
Support for your patients
Discover the selection of support materials for patients from different therapeutic areas
MyPal Support Program
SCORAD
Dupixent Patient Support Program
EASI Calculator
ADCT Tool
Dose adjustment of insulins and other medications during Ramadan
Cardio-Risk app
MyPal Support Program Inquiry Form
N-Pass Tool
How to diagnose Fabry Disease
How to diagnose Pompe Disease
N-PASS Follow Up Form
Sanofi in News
Discover headline news on how Sanofi is engaged with the medical community
Ministry of Health organizes "KiDS" program at Expo 2020 Dubai to promote diabetes awareness at schools
Sanofi signs multi-pronged partnership with Dasman Diabetes Institute to intensify diabetes prevention in Kuwait
Saudi Health Council, Sanofi partner to boost diabetes studies and research in the kingdom
Our Products
Amaryl®
Glimepiride is an orally active hypoglycaemic substance belonging to the sulfonylurea group. It may be used in non-insulin dependent diabetes mellitus.
Aprovel®
Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin-II used to Effectively control Hypertension to normal Rates.
Aubagio®
AUBAGIO® is a once-daily oral tablet that is indicated for adult patients with relapsing remitting multiple sclerosis (RRMS)
Clexane®
Enoxaparin Sodium is a low molecular weight heparin (LMWH) that is administered subcutaneously and used as antithrombotic agent.
Dupixent®
Is a fully human monoclonal antibody with multiple indications in different therapeutic areas.
Lantus®
Insulin Glargine 100, a long-acting insulin administered subcutaneously and used to treat diabetes mellitus in adults, adolescents and children from the age of 2 years.
Lemtrada®
Lemtrada® is a monoclonal antibody produced in mammalian cells (Chinese Hamster Ovary).
Plavix®
Clopidogrel is an inhibitor of platelet aggregation administered orally and indicated for Secondary prevention of atherothrombotic events.
Praluent®
Alirocumab is a fully human IgG1 monoclonal antibody. It’s a PCSK9 inhibitor that is administered subcutaneously.
Renvela®
Sevelamer Carbonate is indicated for the control of hyperphosphatemia in adult patients receiving haemodialysis or peritoneal dialysis. The recommended starting dose of sevelamer carbonate is 2.4 g or 4.8 g per day and must be taken 3 times per day with meals.
Sarclisa®
Isatuximab is an immunoglobulin G1 (IgG1) monoclonal antibody (mAb) for the treatment of adult patients with relapsed and refractory multiple myeloma in combined regimens.
Solian®
Amisulpride is a once-daily dose used for the treatment on schizophrenia if the dose is less than 400mg and twice-daily if the dose exceeds 400mg
Soliqua®
Combination of Insulin Glargine (a basal insulin analog) & Lixisenatide (a GLP-1 receptor agonist) administered subcutaneously.
Tavanic®
Levofloxacin is used in adults for the treatment of infections. The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen.
Toujeo®
Insulin Glargine 300, a long-acting insulin administered subcutaneously and used to treat diabetes mellitus in adults, adolescents and children from the age of 6 years.
Zympass®
Combination of Rosuvastatin Calcium & Ezetimibe used as adjunct to diet for treatment of Primary Hypercholesterolemia or Homozygous Familial Hypercholesterolemia.
▼This drug is subject to additional monitoring, the reporting of suspected adverse reactions associated with this drug is a priority.
YOU WILL NOW BE LEAVING THE SITE
By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.